Clinical Trial

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers， a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers，a single subcutaneous injection of GenSc134 is in AGHD patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-09; most recent amendment 2026-04-12.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT07016802
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Safety, Tolerability, Adult Growth Hormone Deficiency
Enrollment 64 participants
Start Date 2025-06-09
Primary Completion 2026-11-25 (estimated)
Study Completion 2026-11-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-14